Spotlight on Research 2016

January 2016

MRI Findings Reveal Early Changes to Joint That Predict Development of Knee Osteoarthritis
Study challenges widely held belief that damage to cartilage alone initiates disease

Using magnetic resonance imaging (MRI), a team of scientists has detected structural changes in the knee joint that precede signs of osteoarthritis seen on X-rays. The study, which was supported in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), calls into question the assumption that damage to cartilage is the primary underlying cause of osteoarthritis. The findings appeared in the journal Arthritis and Rheumatology.

Osteoarthritis is a common chronic condition of the joints characterized by breakdown of the cartilage that cushions the ends of the bones, bony changes in the joints, and inflammation of the joint lining. It tends to affect heavily used joints such as those in the hands and spine, and the weight-bearing joints in the knees and hips.

For decades, the prevailing view has been that osteoarthritis stems primarily from wear and tear on the cartilage in the joint. Osteoarthritis is often diagnosed using characteristics visible on X-rays, such as narrowing of the joint space, which occurs as the cartilage breaks down, and development of bone spurs, which can form at the edges of the joint.

MRI image of a knee.

Besides cartilage damage (black arrowhead), other joint
tissue changes visible only on MRI, such as a torn meniscus
(large arrow), signs of inflammation (asterisk) or bone marrow
lesions (small arrows) have been found to be important triggers
of knee osteoarthritis. Courtesy of Frank W. Roemer, Boston
University School of Medicine and the University of Erlangen
-Nuremberg.

But recently, studies using MRI, a technology that enables researchers to visualize all the joint’s tissues, have revealed that changes throughout the joint are associated with osteoarthritis. These findings suggested that factors other than loss of cartilage may contribute to disease onset.

In this study, a team led by Frank W. Roemer, M.D., of the Boston University School of Medicine and the University of Erlangen-Nuremberg, set out to assess if structural features detectable by MRI can predict the changes seen on X-rays. If so, the MRI findings could help identify people at risk of joint degeneration. They may also yield insights into the early stages of the disease and guide research on therapies to slow or stop its onset.

The team used data from the Osteoarthritis Initiative External Web Site Policy, a nationwide, NIH-supported observational study of knee osteoarthritis occurrence and progression. The initiative included nearly 5,000 participants, ranging in age from 45 to 79 years when they joined the study. MRI and X-ray knee images were taken at the first visit, and again yearly for four years.

The researchers compared the MRI images of 355 "case knees"—knees that developed osteoarthritis within the four-year period, as determined by characteristic signs seen on X-rays–to 355 matched control knees. They found that two years prior to the development of radiographic knee osteoarthritis, the case knees were more likely to have shown signs of inflammation and damage to the medial meniscus, a crescent-shaped segment of cartilage on the inner side of the knee joint.

Inflammation and lesions in the bone marrow of the leg bones that border the joint were the most prominent predictors of the development of radiographic osteoarthritis one year later. Conversely, cartilage damage did not strongly correlate with the occurrence of radiographic knee osteoarthritis one to two years later, suggesting that cartilage breakdown plays a lesser or later role in the development of the disease.

The study also showed that patients with more abnormalities seen by MRI were more likely to develop radiographic osteoarthritis later on. Five or six structural knee anomalies brought a six-fold increased risk of developing the disease two years later, compared to having one or no MRI-observable structural defects.

Together, the findings suggest that cartilage damage may not be central to the development of osteoarthritis. Clinicians should consider a more nuanced view in which multiple factors are at play, setting the stage for the disease many months earlier than previously assumed, according to the researchers.

"For many years, much of the research on therapies for osteoarthritis has focused on preserving the integrity of joint cartilage," said Dr. Roemer. "Our work has provided a more detailed picture of how we view the events leading up to osteoarthritis, and has uncovered risk factors that will help us understand how the disease develops. Hopefully, it will lead to the identification of novel therapeutic targets."

NIAMS supported this work through the Osteoarthritis Initiative, a public–private partnership between the NIH (contracts N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) and private funding partners (Merck Research Laboratories, Novartis Pharmaceuticals, GlaxoSmithKline, and Pfizer, Inc.). The image analyses (Pivotal OAI MRI Analyses — POMA) were funded by the NIH’s National Heart, Lung, and Blood Institute (contract HHSN2682010000 21C).

Kirstie Saltsman, Ph.D.

# # #

What comes first? Multitissue involvement leading to radiographic osteoarthritis: magnetic resonance imaging-based trajectory analysis over four years in the osteoarthritis initiative. Roemer FW, Kwoh CK, Hannon MJ, Hunter DJ, Eckstein F, Fujii T, Boudreau RM, Guermazi A. Arthritis Rheumatol. 2015 May;67(8):2085-96. doi: 10.1002/art.39176. PMID: 25940308

The mission of the NIAMS, a part of the U.S. Department of Health and Human Services' National Institutes of Health, is to support research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For more information about the NIAMS, call the information clearinghouse at (301) 495-4484 or (877) 22-NIAMS (free call) or visit the NIAMS website at https://www.niams.nih.gov.